RT Journal Article
SR Electronic
T1 MATRIX METALLOPROTEINASE 26 (MMP-26) OVEREXPRESSION IN PROSTATIC ADENOCARCINOMA
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.28.21257789
DO 10.1101/2021.05.28.21257789
A1 Romildo Luciano da Silva
A1 Ingrid Tavares de Lima
A1 Francisco Luís Almeida Paes
A1 Sandra Maria Souza da Silva
A1 Ana Pavla Almeida Diniz Gurgel
A1 Fabiano Santos
A1 Jacinto da Costa Silva Neto
YR 2021
UL http://medrxiv.org/content/early/2021/05/29/2021.05.28.21257789.abstract
AB Introduction Matrix metalloproteinases (MMP) have been identified as biomarkers for several diseases, including cancer. MMP-26 is constitutively expressed in some cancer cells of epithelial origin. Despite this, there is a lack of studies regarding the expression of MMP-26 on prostatic carcinoma.Aim Here, we investigate the expression of the MMP-26 peptide in benign and malign prostatic tissues.Patients and Methods For this, 150 specimens, including atrophy (N = 25), prostatic intraepithelial neoplasia (PIN) (N = 25), benign prostatic hyperplasia (BPH) (N = 50), and prostatic adenocarcinoma (PA) (N = 50), were immunohistochemically (IHC) examined for the expression of MMP-26.Results MMP-26 expression was positive in 70 (46.7%) out of the 150 samples, being more prevalent in the PA group (46/50 cases,92%), followed by PIN (22/25 cases, 88%). The BPH group showed only 2/50 (4%) positive cases, and the atrophy group showed no reactivity. ROC curve analysis showed that MMP-26 immunoexpression had a higher area under the curve between PA vs atrophy+PIN+BPH (AUC=0.94; 95% CI 0.9-0.98), PA+PIN vs atrophy+BPH (AUC=0.97; 95% CI 0.94-0.99) and PA vs atrophy+BPH (AUC=0.97; 95% CI 0.95-1.00) groups. In addition, the expression and intensity of the MMP-26 reaction showed a significant association with total PSA values (P=0.001).Conclusions Our results showed that MMP-26 immunoexpression was useful to differentiate a group of benign and malignant samples in prostate tumors. This characteristic could assist in the predictive assessment and, consequently, in the development of new strategies for the diagnosis, prognosis, and treatment of prostate cancer.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Council for Scientific and Technological Development, CNPq/BrazilAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UFPE research ethics board reviewed the protocol and approved the study (approval number CAAE 79701517100005208)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article.